China's JW rises on licence deal with major shareholder

JW (Cayman) Therapeutics Co

21/12/2022 03:50

** Shares of Chinese cell therapies developer JW (Cayman)
Therapeutics Co Ltd  2126.HK  rise as much as 3.7% to HK$4.17;
on course for their biggest daily pct rise since Dec 9, if gains
hold
    ** Stock set to snap its five-session losing streak
    ** Shanghai-based company says it has secured a deal with
major shareholder, Juno Therapeutics, to establish an alliance
for research and development, manufacturing and
commercialization in China of new cellular therapy products,
specifically directed to a solid tumour antigen known as DLL3
    ** Says the license and collaboration agreement with Juno, a
unit of Bristol Myers Squibb  BMY.N , will accelerate the
development of its cell immunotherapy products to serve more
cancer patients in China and worldwide
    ** The Hang Seng Commerce & Industry Index  .HSNC  climbs
0.4% and healthcare index  .HSCIH  rises 1.7%
    ** The Hang Seng Composite Index  .HSCI  gains 0.4% and the
Hang Seng Index  .HSI  up 0.3%
    ** As of last close, the stock was down 70.1% for the year
 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))